call. joining for Erika. the Thanks all to Thanks,
I have focus we very I think areas. this quarter. had a will on productive on three And call,
cash flows significant deal will sheet. a future impact on positive on a closed just balance our have that we First, and have
And Phase data clinical the and I agreement of will a partnering trial reached support from reported trial accelerated the for design recently progress provide for we of the RSV. with expected, licensure. our The pathway we FDA approval efforts as the on will regulatory finally, use this for NanoFlu. on III our Next,
We deal significantly capacity to recent infrastructure of which raised our our and time, same Paragon its the Paragon Novavax Paragon was with Gene the expertise manufacturing closing capital. their growing last to And This So, manufacturing Therapy rate. the in our with deal, Catalent and burn the strategy business. start reduced agreement unit. Catalent let’s personnel, week acquired Biologics win-win maintain for us allowed and access GMP at a
of approximately So briefly, key material and some development related and of in include: to employees. addition product Novavax approximately facilities million of leases purchase XXX $XX the to Novavax agreement points its and in the Paragon manufacturing now employing for assumed X is cash, equipment
the Paragon activities. a development the quarter. programs, initiate we for of into Novavax later clinical including license applications this The arrangement NanoFlu services to will agreement, in this of impact and the allow part post-licensure long-term us biologics deal with of III entered trial As process support and to of for Phase our specified provide manufacturing third
is market. on this immunogenic II compared which moving the NanoFlu, vaccine quarter older differentiated, as best-selling in trial demonstrated a clinical reminder, to flu that is first more So to Fluzone Phase the a year, a NanoFlu broadly in when we vaccine in flu adult the High-Dose, of
effectiveness, low to confident HXNX flu created for shown which initiate vaccines, the the in seasons. strains, that we as the particularly confidence our recombinant this quadrivalent, flu in we NanoFlu current have close proprietary our will that responses immune in we by vaccine that year potential So NanoFlu III have management. to The similar Phase Matrix-M clinical saw is are protein highlighted the with Likewise, plan see to nanoparticle gives a vaccine results immunogenic robust includes earlier us recent fall. this been gap egg-based we trial
immunogenicity marker inhibition, NanoFlu the design hemagglutinate will NanoFlu. clinical share vaccines. response The has as agreement trial antibody June, the of for with against III this surrogate HAI responses we noninferiority trial will of seasonal is acknowledged efficacy to the that to we that the you previously approval flu a compare NanoFlu. Earlier pleased licensure HAI, in on of And the with upcoming or licensed expect licensure of week, remind were we FDA future vaccine reached announced comparator. Phase flu accelerated support pathway we the biologics a available is for And FDA that of you,
with expect top following completion clinical file have data a line to U.S. of required positive to the and of manufacturing plan we quarter in first activities. We XXXX BLA results validation
in activities plans the We will coming frames for as these refine we quarters. our announce time
we the and complete filing the very BLA short to efficiently We like would positioned here are that are our significant at I well for to clinical our NanoFlu a development through of of our thank licensure. effectively currently Novavax in confident the to to and team NanoFlu program cost advances to timeline.
the And data move III recently completed significant that public with consequences from now a Phase infants, the further health belief RSV. in believe to protection RSV support licensure. development demonstrated trial, prepared key our of our global We, I along for provide clinical clinical on that these can clinical RSV and which that warrants benefit serious leaders, vaccine ResVax, opinion maternal vaccine
potential and We commercialization. are global forward working to with path regulatory determine partners to best agencies the
in continue to regulatory significant efficacy licensure, of agencies reported which short other this trial and ResVax. the FDA benefits earlier endpoint, the to Phase vaccine And on has conduct important In regulatory RSV input pathways demonstrated process. announced against solicit primary we Europe, potential III experts as But against that Phase an vaccinated meeting disease. important June, clinical additional complicates U.S. for of year, medically to forms we severe licensure. recommended the with we confirm mothers most clinical disease we approval the we that RSV in III our born from national to infants trial clinical As our fell
be will the fall from We formal scientific seeking Agency. Medicines this advice European
to countries. and ResVax for a path introducing middle-income We working low also are to identify
in high-income with at countries, research and our brief I ongoing continuing Foundation data in Gates XXXX. development PATH, We potential help with important to parallel Melinda for note further & our discussions better have early steps the on the in global partner this we partners efforts these move full launched expect these We with to to Bill hope with partners should review or we and of the understand the including of are our vaccine. to the you year that later U.S. our potential further along
this these Obstetrics important week Dr. Provost is the Obstetrics and Associate be findings and IDSOG discussed Dr. which Some a Infectious Gynecology, Vice Scientific Professor and will of Swamy, University. in Vice of efficacy August at for Society at for Duke Diseases Associate Dean later annual Swamy Friday. Integrity Geeta at conference by presentation this new will and on present the the meeting, Gynecology X
We timing a be in opportunity offer the place, ResVax in of licensed partnerships the can vaccine release. that will press We remain to the separate right announce the confident an with in RSV presentation first that world.
to And now I financial turn the present John over to will call overview. the
